ICH Q3C Residual Solvents: Classification, Limits, and Testing
ICH Q3C(R8) classifies residual solvents in pharmaceuticals into three classes based on toxicity: Class 1 (should be avoided, e.g., benzene, carbon tetrachloride), Class 2 (limited use, with compound-specific PDE limits, e.g., methanol at 30 mg/day, dichloromethane at 6 mg/day), and Class 3 (low toxicity, permitted up to 50 mg/day or 5000 ppm, e.g., ethanol, acetone). Testing is typically performed by headspace gas chromatography (HS-GC), with Option 1 (universal limits in ppm) and Option 2 (product-specific limits based on daily dose) available for setting acceptance criteria.
Key Takeaways
Key Takeaways
- Class 1 solvents (benzene, carbon tetrachloride) should be avoided; Class 2 solvents have compound-specific PDE limits; Class 3 solvents are permitted up to 50 mg/day or 5000 ppm.
- Headspace gas chromatography (HS-GC) is the standard analytical method for residual solvent testing in pharma.
- Option 1 uses universal concentration limits (ppm) applicable to any product; Option 2 calculates product-specific limits based on maximum daily dose.
- ICH Q3C(R8) applies to drug substances, excipients, and drug products; the current revision (April 2021) added 2-MeTHF as a Class 3 solvent.
- ICH Q3C(R8) — "Residual Solvents" — provides the internationally harmonized framework for controlling residual solvents in pharmaceutical drug substances, excipients, and drug products. The current revision (R8) was published in April 2021, incorporating 2-methyltetrahydrofuran (2-MeTHF) as a Class 3 solvent.
- Residual solvents are volatile organic compounds that are used or produced during the manufacture of drug substances, excipients, or drug products. Because they provide no therapeutic benefit and may be toxic, their levels must be controlled and documented.
- Unlike ICH Q3A/Q3B (which address organic impurities as percentages of drug substance), residual solvent limits under Q3C are expressed as absolute concentrations (ppm) or Permitted Daily Exposures (mg/day), reflecting their distinct toxicological assessment.
- In this guide, you'll learn:
- ICH Q3C solvent classification system (Class 1, 2, 3)
- PDE values and concentration limits for commonly used solvents
- Option 1 vs. Option 2 approaches for setting specifications
- Headspace GC testing methodology and alternatives
- Loss on drying vs. residual solvent testing
- Practical considerations for CMC teams
- ---
Solvent Classification System
Class 1: Solvents to Be Avoided
Class 1 solvents are known human carcinogens, strongly suspected human carcinogens, or environmental hazards. They should not be employed in the manufacture of drug substances, excipients, or drug products. If their use is unavoidable, they must be controlled to very low levels with documented justification.
| Solvent | Concentration Limit (ppm) | PDE (mg/day) | Toxicity Concern |
|---|---|---|---|
| Benzene | 2 | 0.02 | Known human carcinogen (IARC Group 1) |
| Carbon tetrachloride | 4 | 0.04 | Hepatotoxicity; probable carcinogen |
| 1,2-Dichloroethane | 5 | 0.05 | Probable carcinogen |
| 1,1-Dichloroethene | 8 | 0.08 | Hepatotoxicity; renal toxicity |
| 1,1,1-Trichloroethane | 1500 | 15 | Environmental hazard (ozone depletion) |
The mere detection of a Class 1 solvent does not automatically disqualify a product. ICH Q3C permits Class 1 solvents when "their use is unavoidable to produce a drug product with a significant therapeutic advance." However, expect detailed justification requirements in the regulatory submission. Document why no alternative solvent can achieve the same synthetic objective.
Class 2: Solvents to Be Limited
Class 2 solvents are non-genotoxic but have significant toxicity. Their use should be limited through adherence to PDE values. This is the largest class, containing the most commonly encountered solvents in pharmaceutical manufacturing.
Commonly used Class 2 solvents:
| Solvent | PDE (mg/day) | Concentration Limit (ppm) — Option 1 | Primary Toxicity |
|---|---|---|---|
| Acetonitrile | 4.1 | 410 | CNS toxicity |
| Chloroform | 0.6 | 60 | Hepatotoxicity; carcinogenicity concern |
| Cyclohexane | 38.8 | 3880 | CNS toxicity |
| Dichloromethane (DCM) | 6.0 | 600 | CNS toxicity; potential carcinogenicity |
| N,N-Dimethylacetamide (DMA) | 10.9 | 1090 | Hepatotoxicity; reproductive toxicity |
| N,N-Dimethylformamide (DMF) | 8.8 | 880 | Hepatotoxicity; reproductive toxicity |
| 1,4-Dioxane | 3.8 | 380 | Potential carcinogenicity |
| Methanol | 30.0 | 3000 | Optic nerve toxicity; CNS depression |
| 2-Methoxyethanol | 0.5 | 50 | Hematotoxicity; reproductive toxicity |
| N-Methylpyrrolidone (NMP) | 5.3 | 530 | Reproductive toxicity |
| Pyridine | 2.0 | 200 | Hepatotoxicity; CNS toxicity |
| Tetrahydrofuran (THF) | 7.2 | 720 | CNS toxicity |
| Toluene | 8.9 | 890 | CNS toxicity; reproductive toxicity |
The complete Class 2 listing is in ICH Q3C(R8) Table 2. The full list with PDE values is in ICH Q3C(R8) Appendix 2.
Class 3: Solvents with Low Toxic Potential
Class 3 solvents have low toxicity and do not require individual testing when the drug substance is manufactured under GMP. No adequate toxicological data exists to require a lower limit, so a general PDE of 50 mg/day (5000 ppm using Option 1) applies.
Common Class 3 solvents:
| Solvent | PDE (mg/day) | Concentration Limit (ppm) — Option 1 |
|---|---|---|
| Acetic acid | 50 | 5000 |
| Acetone | 50 | 5000 |
| 1-Butanol | 50 | 5000 |
| Ethanol | 50 | 5000 |
| Ethyl acetate | 50 | 5000 |
| Ethyl formate | 50 | 5000 |
| Heptane | 50 | 5000 |
| Isobutyl acetate | 50 | 5000 |
| Isopropyl acetate | 50 | 5000 |
| Methyl acetate | 50 | 5000 |
| 2-Methyltetrahydrofuran | 50 | 5000 |
| 3-Methyl-1-butanol | 50 | 5000 |
| Pentane | 50 | 5000 |
| 1-Propanol | 50 | 5000 |
| 2-Propanol (IPA) | 50 | 5000 |
| Propyl acetate | 50 | 5000 |
2-Methyltetrahydrofuran (2-MeTHF) was added as a Class 3 solvent in the R8 revision (2021). If your regulatory submission references an older version of Q3C, 2-MeTHF may not appear in the solvent list. Confirm that your regional regulatory authority has adopted Q3C(R8) and cite the correct revision in your CTD.
Solvents Not Classified by ICH Q3C
Some solvents used in pharmaceutical manufacturing are not included in any ICH Q3C class. These require case-by-case assessment:
| Situation | Approach |
|---|---|
| Solvent not in Q3C at all | Derive PDE from published toxicological data using the ICH Q3C methodology (NOAEL, uncertainty factors) |
| Solvent with inadequate data | Use a conservative default limit (50 ppm) or generate toxicological data |
| Novel "green" solvents | Apply Q3C methodology; consider Q3C(R9) for potential future inclusion |
Option 1 vs. Option 2 Approaches
ICH Q3C provides two options for setting residual solvent specifications. The choice between them depends on how many products a drug substance is used in and whether daily dose information is available.
Option 1: Concentration Limits in ppm (Universal)
Option 1 establishes concentration limits in ppm that apply regardless of the daily dose. These limits are calculated assuming a maximum daily dose of 10 g/day.
Option 1 calculation:
When to use Option 1:
- Drug substance is used in multiple drug products with different daily doses
- Daily dose is not yet finalized (early development)
- Excipient specifications (daily dose varies by formulation)
- When simplicity is preferred and limits are achievable
Advantage: Single specification applicable to all products
Disadvantage: May be unnecessarily tight for low-dose products; may be too permissive for high-dose products
Option 2: Product-Specific Limits Based on Daily Dose
Option 2 calculates limits based on the actual maximum daily dose of the specific drug product.
Option 2 calculation:
Worked example:
| Drug Product | MDD | PDE for DCM | Option 1 Limit | Option 2 Limit |
|---|---|---|---|---|
| Product A | 50 mg (0.05 g) | 6.0 mg/day | 600 ppm | 120,000 ppm |
| Product B | 500 mg (0.5 g) | 6.0 mg/day | 600 ppm | 12,000 ppm |
| Product C | 5 g | 6.0 mg/day | 600 ppm | 1,200 ppm |
| Product D | 10 g | 6.0 mg/day | 600 ppm | 600 ppm |
When to use Option 2:
- Daily dose is well-defined and approved
- Option 1 limits are not achievable and a product-specific limit is needed
- High-dose products where Option 1 may be insufficient (dose > 10 g/day)
Option 2 can produce very large ppm limits for low-dose products (e.g., 120,000 ppm for a 50 mg product with DCM). While mathematically correct, a specification of 12% residual DCM would be unusual and might draw regulatory questions. Use scientific judgment: if Option 2 produces a limit > 5000 ppm for a Class 2 solvent, consider whether a tighter limit is more appropriate based on manufacturing capability.
Headspace GC Testing
Why Headspace GC?
Headspace gas chromatography (HS-GC) is the standard technique for residual solvent analysis because:
- Solvents are volatile, making headspace sampling ideal
- Matrix interference is minimized (non-volatile API and excipients remain in the vial)
- High sensitivity achievable (low ppm detection limits)
- Simultaneous multi-solvent analysis is feasible
HS-GC Method Design
| Parameter | Typical Conditions | Rationale |
|---|---|---|
| Equilibration temperature | 80-120C | Must be high enough to volatilize target solvents |
| Equilibration time | 30-60 minutes | Must achieve vapor-liquid equilibrium |
| Carrier gas | Helium or nitrogen | Inert carrier for GC column |
| Column | DB-624 (mid-polarity) or DB-WAX (polar) | Separates common solvents; DB-624 is most common |
| Detector | FID (flame ionization) | Universal organic compound detection; quantitative |
| Injection | Headspace autosampler | Automated, reproducible sampling |
| Diluent | Water, DMSO, DMF, or NMP | Must dissolve the sample completely |
Method Validation Requirements (Per ICH Q2(R2))
ICH Q2(R2) does not prescribe a single universal numeric acceptance table for every residual solvent method. Instead, the method should be validated against scientifically justified performance criteria that fit the intended use, matrix, and reporting range.
| Validation Parameter | What to Demonstrate |
|---|---|
| Specificity | Target solvents are distinguished from each other, the diluent, and matrix peaks |
| Range / reportable range | The method performs acceptably across the concentrations that matter for the specification |
| Accuracy | Recovery is suitable for the intended concentration range and matrix |
| Precision | Repeatability and intermediate precision are acceptable for the reporting level |
| Detection / quantitation capability | The method can reliably detect or quantify solvents at the needed threshold |
| Robustness | Small changes in parameters such as equilibration time, temperature, or sample preparation do not compromise suitability |
Alternative Analytical Techniques
| Technique | When Used | Advantage |
|---|---|---|
| Direct injection GC-FID | Non-volatile matrices; solvents with very high boiling points | No headspace transfer losses |
| GC-MS | Identification of unknown solvents; specificity confirmation | Structural identification |
| HS-GC-MS | Confirmation of identity; resolving co-eluting peaks | Spectral confirmation |
| HS-SPME-GC | Very low-level solvents; trace analysis | Enhanced sensitivity |
Loss on Drying vs. Residual Solvent Testing
A common question in pharmaceutical quality is whether loss on drying (LOD) testing can substitute for residual solvent testing.
Loss on Drying (LOD)
LOD measures the total weight loss of a sample when dried under specified conditions (temperature, vacuum, desiccant, duration). It measures total volatile content including water.
| LOD Characteristic | Detail |
|---|---|
| What it measures | Total weight loss (water + solvents + any volatile material) |
| Specificity | Non-specific; cannot distinguish between water and solvents |
| Typical conditions | 105C for 2 hours, or vacuum desiccator at 60C |
| Pharmacopeial method | USP <731>, PhEur 2.2.32 |
When LOD Can Replace Residual Solvent Testing
ICH Q3C permits LOD as a surrogate for residual solvent testing under specific conditions:
For Class 3 solvents only:
- If only Class 3 solvents are used in the final manufacturing step
- If LOD result is ≤ 0.5% (5000 ppm), the product meets Q3C requirements without specific solvent identification
- The manufacturer must document which solvents are used and confirm they are all Class 3
This substitution is NOT acceptable when:
- Class 1 or Class 2 solvents are used at any point in the drug substance or excipient manufacturing
- The LOD result exceeds 0.5%
- Regulatory authority specifically requests residual solvent identification
Many drug substance manufacturers use Class 2 solvents in early synthetic steps and Class 3 solvents only in the final step. In this case, LOD alone is insufficient. You must test for the Class 2 solvents used in earlier steps unless purge data demonstrates their complete removal. A common regulatory deficiency is claiming LOD sufficiency when Class 2 solvents were used upstream.
Practical Decision Matrix
| Solvents Used | Testing Required | LOD Sufficient? |
|---|---|---|
| Class 3 only (final step) | LOD ≤ 0.5% | Yes |
| Class 3 only (final step), LOD > 0.5% | HS-GC for Class 3 solvents | No |
| Class 2 in any step | HS-GC for specific Class 2 solvents | No |
| Class 1 in any step | HS-GC for specific Class 1 solvents | No |
| Class 2 in early steps, Class 3 in final step | HS-GC for Class 2; LOD may cover Class 3 if ≤ 0.5% | Partial |
Specification Setting
Drug Substance Specifications
| Scenario | Specification Approach |
|---|---|
| Known solvents, Option 1 | List each solvent with Option 1 ppm limit in the drug substance specification |
| Known solvents, Option 2 | List each solvent with calculated product-specific ppm limit |
| Class 3 only, LOD approach | LOD NMT 0.5% |
| Multiple solvents | Individual limits for each; may include total solvents limit |
Drug Product Specifications
Residual solvent testing is generally performed at the drug substance level. Drug product specifications for residual solvents are typically not required unless:
- Solvents are used in drug product manufacturing (e.g., film coating solvents, granulation solvents)
- The drug product manufacturing process could introduce residual solvents from excipients
Excipient Considerations
Drug substance manufacturers may not always know the full solvent history of excipients used in the drug product. ICH Q3C addresses this:
- Excipient manufacturers should report solvents used in excipient manufacture
- Drug product manufacturers should evaluate the residual solvent contribution from excipients
- Pharmacopeial excipient monographs may include residual solvent limits
Special Cases and Frequently Asked Questions
Multi-Solvent Products
When multiple Class 2 solvents are present, the total daily intake of all solvents should be evaluated. ICH Q3C does not require that total solvent intake be limited, but individual PDE limits must be met for each solvent independently.
Solvent Mixtures
If a 50:50 mixture of two Class 2 solvents is used, each must individually meet its own PDE limit. The limits are not additive — each solvent is assessed independently unless they share the same toxicological target organ, in which case additive toxicity should be considered.
Carry-Over from Starting Materials
If a starting material supplier uses Class 1 or Class 2 solvents, the drug substance manufacturer must assess whether these solvents carry through to the final drug substance. Options:
- Obtain solvent usage information from the supplier (required per ICH Q7)
- Test the starting material for residual solvents
- Demonstrate purge through downstream processing steps
Water as a Residual Solvent
Water is not classified under ICH Q3C. Water content is controlled separately through Karl Fischer titration (ICH Q6A, USP <921>) or LOD testing. The total volatile content measured by LOD includes water.
Key Takeaways
References
Key Takeaways
- 1. Three classes with different risk levels: Class 1 (avoid; carcinogens/environmental hazards), Class 2 (limit per PDE), Class 3 (low toxicity; 50 mg/day or 5000 ppm general limit).
- 2. Option 1 is universal, Option 2 is product-specific: Option 1 assumes 10 g/day dose and sets fixed ppm limits. Option 2 calculates limits from actual daily dose. Option 2 is more permissive for low-dose products and more restrictive for high-dose products.
- 3. Headspace GC is the standard method: HS-GC with FID detection provides the sensitivity and specificity needed. Method validation per ICH Q2(R2) is required.
- 4. LOD can replace residual solvent testing for Class 3 only: If only Class 3 solvents are used in the final step and LOD is ≤ 0.5%, no further testing is needed. Class 2 solvents always require specific identification and quantification.
- 5. Know your full solvent history: Every solvent used in every step of manufacturing — including starting material synthesis and excipient manufacture — must be evaluated. Upstream Class 2 solvents cannot be ignored.
- 6. PDE is the basis for all limits: All concentration limits derive from the PDE (mg/day) divided by the daily dose. Use the published PDE values from ICH Q3C(R8) appendices.
- 7. 2-MeTHF is now Class 3: Added in the R8 revision (2021). Confirm your submission references the current Q3C revision.
- ---
- ICH Q3C(R8): Residual Solvents
- ICH Q2(R2): Validation of Analytical Procedures
- ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
- USP <467> Residual Solvents
- USP <731> Loss on Drying